Pacific Edge, the bladder test investor whose share price has more than doubled in the past week, wants to raise as much as $20.5 million from shareholders to fund its growing push into the US, having grabbed a beach-head with two healthcare network providers in the world's biggest economy.
The Dunedin-based company will offer a 2 for 15 renounceable rights issue to investors at 55c apiece.
The company's shares closed up 31c yesterday at $1.37.
The capital raising is expected to ease short- to medium-term risks around Pacific Edge's liquidity.
Of the funds raised, $10.2 million will go to building the company's sales team in the US over the next three years, $6.6 million will be spent on operational expenditure at the US and New Zealand commercial labs, and $3.7 million will go towards new product development, launch and roll-out.